influenza virus rna polymerase

Baloxavir (S-033447) is a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.

Favipiravir is a potent and selective RNA-dependent RNA polymerase inhibitor for the treatment of influenza virus infections.

Cynaroside (Luteolin 7-O-Glucoside) is a flavone, a flavonoid-like chemical compound. It has an anti-oxidant effect, inhibiting lipid and protein oxidation.

T-705RTP is a selective and GTP-competitive of influenza virus RNA polymerase(IC50 of 0.14 μM and a Ki of 1.52 μM), has potent anti-influenza virus activity.

T-705RTP sodium is a selective and GTP-competitive of influenza virus RNA polymerase(IC50 of 0.14 μM and a Ki of 1.52 μM), has potent anti-influenza virus activity.

Ribavirin-13C5is intended for use as an internal standard for the quantification of ribavirin by GC- or LC-MS. Ribavirin is an antiviral guanosine nucleoside analog.1,2Upon entry into cells, ribavirin is metabolized to an active triphosphate form that induces viral RNA chain termination and inhibits viral polymerases. It reduces replication in a panel of seven RNA and four DNA viruses in Vero cells (EC50s = 2-95 μg/ml).3Ribavirin also reduces replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Vero cells (EC50= 109.5 μM).4Aerosol administration of ribavirin (30 mg/kg) reduces mortality in a mouse model of influenza A infection.5Formulations containing ribavirin have been used in the treatment of respiratory syncytial virus (RSV), hepatitis C virus (HCV), and viral hemorrhagic fevers. 1.Gilbert, B.E., and Knight, V.Biochemistry and clinical applications of ribavirinAntimicrob. Agents Chemother.30(2)201-205(1986) 2.Gordon, C.J., Tchesnokov, E.P., Woolner, E., et al.Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potencyJ. Biol. Chem.295(20)6785-6797(2020) 3.Kirsi, J.J., North, J.A., McKernan, P.A., et al.Broad-spectrum antiviral activity of 2-β-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agentAntimicrob. Agents Chemother.24(3)353-361(1983) 4.Wang, M., Cao, R., Zhang, L., et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Res.30(3)269-271(2020) 5.Wilson, S.Z., Knight, V., Wyde, P.R., et al.Amantadine and ribavirin aerosol treatment of influenza A and B infection in miceAntimicrob. Agents Chemother.17(4)642-648(1980)

RdRP-IN-4 (compound 11q) is an arylbenzohydrazide analogue, an orally active inhibitor of influenza A virus RNA-dependent RNA polymerase (RdRp) that directly binds the PB1 subunit of RdRp. RdRP-IN-4 inhibited H1N1 (A PR 8 34) Flu A and Flu B strains (B Lee 1940) in a dose-dependent manner with EC50 values of 53 nM and 20 nM, respectively. RdRP-IN-4 had a significant antiviral effect in infected mice.

Cap-dependent endonuclease-IN-19, a spirocyclic pyridinone derivative, is a potent inhibitor of cap-dependent nucleic acid endonuclease (CEN) and effectively inhibits the RNA polymerase activity of influenza A virus.

Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) and significantly inhibits influenza A virus RNA polymerase activity.

Pimodivir, also known as VX-787, JNJ-872, is a novel inhibitor of influenza virus replication that blocks the PB2 cap-snatching activity of the influenza viral polymerase complex. VX-787 binds the cap-binding domain of the PB2 subunit with a KD (dissociation constant) of 24 nM as determined by isothermal titration calorimetry (ITC). The cell-based EC50 (the concentration of compound that ensures 50% cell viability of an uninfected control) for VX-787 is 1.6 nM in a cytopathic effect (CPE) assay, with a similar EC50 in a viral RNA replication assay. VX-787 is active against a diverse panel of influenza A virus strains, including H1N1pdm09 and H5N1 strains, as well as strains with reduced susceptibility to neuraminidase inhibitors (NAIs).

Favipiravir sodium is a selective inhibitor of viral RNA-dependent RNA polymerase with activity against many RNA viruses, influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses.

Cap-dependent endonuclease-IN-9 is a potent cap-dependent endonuclease (CEN) inhibitor with notable efficacy against the influenza virus, minimal cytotoxicity, enhanced in vivo pharmacokinetics, and robust pharmacodynamics. It effectively suppresses the RNA polymerase activity of Influenza A virus[1].

Trans-RdRP-IN-5 is a potent inhibitor of the influenza virus RNA-dependent RNA polymerase (RdRP), with applications in influenza virus research.

Cis-RdRP-IN-5 is an effective inhibitor of the influenza virus RNA-dependent RNA polymerase (RdRP), employed in influenza virus research.

RdRP-IN-5 (compound 20), a potent inhibitor of the influenza virus RNA-dependent RNA polymerase (RdRP), has potential application in influenza research [1].

Viral polymerase-IN-1 hydrochloride, a derivative of Gemcitabine, effectively inhibits influenza A and B virus infections with IC90 values between 11.4 and 15.9 μM, and shows activity against SARS-CoV-2 infection by interfering with viral RNA replication transcription within cells [1].

Baloxavir-d4 is a deuterated compound of Baloxavir. Baloxavir has a CAS number of 1985605-59-1. Baloxavir is a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.